Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Laboratories, BioSource International, GeneGo and National Cancer Institute, Agilent Technologies and Rosetta Biosoftware, and Innovative Biosensors

Premium

BioRad Completes $200M Exchange Offer for Senior Notes

Bio-Rad Laboratories has completed an exchange offer that allowed holders of $200 million worth of senior subordinated notes acquired through a private sale last year to obtain amended, publicly registered notes as of this week, the company said.

According to Ron Hutton, the treasurer of the Hercules, Calif.-based life sciences firm, Bio-Rad offered the note exchange at the beginning of May to investors that had purchased the 6.125-percent notes, due 2014, in December 2004. The amended notes can be publicly traded, as opposed to the old privately issued notes, Hutton said.


BioSource Receives Nasdaq Delisting Notice

BioSource International said last week that it had received a notice from the Nasdaq indicating that the company is not in compliance with the stock exchange's requirements for continued listing of its shares.

According to BioSource, the reason for the non-compliance is its failure to file a first-quarter financial report in a timely manner. The company said that its failure to do so is related to discussions with external auditors regarding "possible changes to its long-standing accounting policy of reserving for 100 percent of the costs of manufactured antibody inventory."

BioSource said that, in light of these discussions, it plans to restate its financial results for the three years ended December 31, 2004. The company added that a change in its accounting policy is not expected to have any material impact on its previously reported cash flows, and that it expects a net increase in stockholders' equity at December 31, 2004.

The company said that the notice from the Nasdaq indicated its stock would be delisted if a financial report were not filed by June 3. This delisting date has been postponed pending a hearing with the Nasdaq to appeal the ruling, BioSource said.


NCI Licenses GeneGo's Pathway Analysis Software

GeneGo has licensed its pathway analysis software to the National Cancer Institute, the St. Joseph, Mich.-based company said this week.

Under the agreement, all NCI researchers have access to the 2.5 version of GeneGo's MetaCore software through their web browsers, GeneGo said.

MetaCore allows researchers to mine high-throughput experimental data in the context of biological networks, pathways, and diseases.


Agilent, Rosetta Biosoftware to Integrate Gene Expression Analysis Software

Agilent Technologies and Rosetta Biosoftware are integrating the Rosetta Resolver and Agilent GeneSpring software packages for gene expression analysis.

The integration is being facilitated by the Resolver Software Development Kit, the companies said. Further details were not disclosed.

Agilent is the exclusive distributor of the Rosetta's gene expression analysis software.


Innovative Biosensors Nets $3.5M in Series A to Develop Pathogen Detectors

Innovative Biosensors has raised $3.5 million of venture capital in a Series A round, the College Park, Md.-based company said last week.

The company, founded in 2003, uses technology licensed from the Massachusetts Institute of Technology to develop sensitive and fast pathogen detectors for food testing and clinical diagnostics.

Harbert Venture Partners led the financing round and was joined by New Markets Growth Fund and the Maryland Venture Fund.

 

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.